Shares of Beyond Air XAIR moved lower in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 23.26% over the past year to ($0.33), which missed the estimate of ($0.31).
Revenue of $148,794 decreased by 52.67% year over year, which missed the estimate of $270,000.
Outlook
Beyond Air hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 09, 2021
Time: 04:30 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=143050
Recent Stock Performance
Company's 52-week high was at $12.50
52-week low: $3.72
Price action over last quarter: Up 39.10%
Company Description
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company which develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
